# Neoadjuvant chemotherapy-enabled tumor conversion and surgical resection in pediatric primary pulmonary Ewing sarcoma: a case report

**Authors:** Jun-Ping Lin, Chong-Rui Li, Bin Li, Jian-Bao Yang

PMC · DOI: 10.3389/fonc.2026.1723340 · Frontiers in Oncology · 2026-02-16

## TL;DR

A 10-year-old girl with rare lung Ewing sarcoma was successfully treated with chemotherapy and surgery, showing the importance of a multidisciplinary approach.

## Contribution

This case report presents a rare pediatric primary pulmonary Ewing sarcoma successfully treated with neoadjuvant chemotherapy and surgery.

## Key findings

- Neoadjuvant chemotherapy converted an unresectable tumor into a resectable one.
- Surgery followed by adjuvant chemotherapy led to no signs of recurrence in the patient.
- Multidisciplinary management is critical for treating rare pediatric pulmonary Ewing sarcoma.

## Abstract

Ewing sarcoma (EWS) is a highly aggressive malignant tumor that primarily affects the skeletal system in children and adolescents. Primary pulmonary Ewing sarcoma (PPEWS) is extremely rare, particularly in children, with very few cases reported in the literature.

This report describes a 10-year-old girl who was admitted with an intermittent cough lasting over 7 months. Chest computed tomography (CT) revealed a mass in the right lower lung lobe. Bronchoscopic biopsy demonstrated a highly malignant undifferentiated small round cell tumor, with immunohistochemistry confirming EWS (positive for CD99, NKX2.2, and FLI-1). After 8 cycles of VDC/IE neoadjuvant chemotherapy, neoadjuvant therapy enabled tumor conversion from unresectable to resectable status. Postoperative pathology confirmed extraskeletal EWS/peripheral primitive neuroectodermal tumor (pPNET) following right middle and lower lobectomy, with good postoperative recovery. Following a multidisciplinary team (MDT) consensus, the patient initiated adjuvant chemotherapy utilizing the same VDC/IE regimen. As of the latest follow-up, she has successfully completed six cycles of adjuvant chemotherapy, and no clinical or radiological signs of recurrence have been observed.

This case underscores the extreme rarity of PPEWS in children and the complexities of its diagnosis and treatment. Neoadjuvant chemotherapy can facilitate tumor conversion, while surgery plays a pivotal role in localized cases with incomplete chemotherapeutic response. Multidisciplinary management is essential for optimizing outcomes.

## Linked entities

- **Proteins:** CD99 (CD99 molecule (Xg blood group)), NKX2-2 (NK2 homeobox 2), FLI1 (Fli-1 proto-oncogene, ETS transcription factor)
- **Diseases:** Ewing sarcoma (MONDO:0012817), peripheral primitive neuroectodermal tumor (MONDO:0018271)

## Full-text entities

- **Genes:** NKX2-2 (NK2 homeobox 2) [NCBI Gene 4821] {aka NKX2.2, NKX2B}, EWSR1 (EWS RNA binding protein 1) [NCBI Gene 2130] {aka EWS, EWS-FLI1}, SYP (synaptophysin) [NCBI Gene 6855] {aka MRX96, MRXSYP, XLID96}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, VIM (vimentin) [NCBI Gene 7431], FLI1 (Fli-1 proto-oncogene, ETS transcription factor) [NCBI Gene 2313] {aka BDPLT21, EWSR2, FLI-1, SIC-1}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}
- **Diseases:** bronchial compression (MESH:D001982), hyperplasia (MESH:D006965), tuberculosis (MESH:D014376), lymph node metastasis (MESH:D008207), EWS (MESH:D012512), weight loss (MESH:D015431), cough (MESH:D003371), pPNET (MESH:D018241), infective (MESH:D007239), cell tumor (MESH:D005935), metastases (MESH:D009362), pulmonary blastoma (MESH:D018202), neuroblastoma (MESH:D009447), fever (MESH:D005334), hemoptysis (MESH:D006469), pneumonia (MESH:D011014), chest pain (MESH:D002637), respiratory obstruction (MESH:D012131), PNET (MESH:D018242), Tumor (MESH:D009369), calcification (MESH:D002114), lung lesions (MESH:D008171), lung tumors (MESH:D008175), dyspnea (MESH:D004417), round blue cell tumor (MESH:D058405), bronchial obstruction (MESH:D002283)
- **Chemicals:** ifosfamide (MESH:D007069), etoposide (MESH:D005047), FDG (MESH:D019788), doxorubicin (MESH:D004317), H&amp;E (MESH:D006371), VDC (-), cyclophosphamide (MESH:D003520), vincristine (MESH:D014750)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950571/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950571/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950571/full.md

---
Source: https://tomesphere.com/paper/PMC12950571